LABS Stock Overview
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MediPharm Labs Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.08 |
| 52 Week High | CA$0.10 |
| 52 Week Low | CA$0.055 |
| Beta | 0.97 |
| 1 Month Change | 14.29% |
| 3 Month Change | 14.29% |
| 1 Year Change | -11.11% |
| 3 Year Change | -82.98% |
| 5 Year Change | -98.68% |
| Change since IPO | -96.36% |
Recent News & Updates
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost
Mar 23
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Jan 10Recent updates
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost
Mar 23Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Jan 10MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?
Sep 06MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 17Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook
Aug 20Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates
May 21Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade
Apr 06Is MediPharm Labs (TSE:LABS) Using Too Much Debt?
Mar 07Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Aug 18Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates
May 23Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year
Jan 11
Shareholder Returns
| LABS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -5.9% | -9.9% | -3.0% |
| 1Y | -11.1% | 46.0% | 3.2% |
Return vs Industry: LABS underperformed the Canadian Pharmaceuticals industry which returned 44.4% over the past year.
Return vs Market: LABS underperformed the Canadian Market which returned 3.9% over the past year.
Price Volatility
| LABS volatility | |
|---|---|
| LABS Average Weekly Movement | 14.3% |
| Pharmaceuticals Industry Average Movement | 14.1% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: LABS has not had significant price volatility in the past 3 months.
Volatility Over Time: LABS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 166 | David Pidduck | www.medipharmlabs.com |
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada and internationally. The company formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. It also provides GMP flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll products.
MediPharm Labs Corp. Fundamentals Summary
| LABS fundamental statistics | |
|---|---|
| Market cap | CA$32.32m |
| Earnings (TTM) | -CA$13.08m |
| Revenue (TTM) | CA$33.06m |
1.0x
P/S Ratio-2.5x
P/E RatioIs LABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LABS income statement (TTM) | |
|---|---|
| Revenue | CA$33.06m |
| Cost of Revenue | CA$24.96m |
| Gross Profit | CA$8.10m |
| Other Expenses | CA$21.18m |
| Earnings | -CA$13.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 24.50% |
| Net Profit Margin | -39.57% |
| Debt/Equity Ratio | 4.0% |
How did LABS perform over the long term?
See historical performance and comparison